` TNXP (Tonix Pharmaceuticals Holding Corp) vs S&P 500 Comparison - Alpha Spread

TNXP
vs
S&P 500

Over the past 12 months, TNXP has underperformed S&P 500, delivering a return of -74% compared to the S&P 500's 9% growth.

Stocks Performance
TNXP vs S&P 500

Loading
TNXP
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
TNXP vs S&P 500

Loading
TNXP
S&P 500
Difference
www.alphaspread.com

Performance By Year
TNXP vs S&P 500

Loading
TNXP
S&P 500
Add Stock

Competitors Performance
Tonix Pharmaceuticals Holding Corp vs Peers

S&P 500
TNXP
ABBV
AMGN
GILD
VRTX
Add Stock

Tonix Pharmaceuticals Holding Corp
Glance View

Market Cap
236m USD
Industry
Biotechnology

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 73 full-time employees. The company went IPO on 2010-03-29. The company is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) and infectious disease product candidates. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases, and cancer. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its infectious disease portfolio of product candidates includes vaccines to prevent COVID-19, an antiviral to treat COVID-19, and treatment for long COVID. The infectious disease portfolio also includes a vaccine in development to prevent smallpox and monkeypox. Its product candidates include TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR, and TNX-1900.

TNXP Intrinsic Value
21.5 USD
Overvaluation 37%
Intrinsic Value
Price
Back to Top